Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

# Artivion, Inc.

Artivion manufactures, processes, and distributes medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

## Product families

- Aortic stent grafts (for aortic arch and abdominal disease; includes synthetic vascular grafts)
  - Aortic arch stent graft systems: E-vita Open NEO, E-vita Open Plus, Arcevo LSA Hybrid Stent Graft System (Arcevo LSA), AMDS hybrid prosthesis, NEXUS ONE, NEXUS DUO, NEXUS TRE, E-vita Thoracic 3G
  - Abdominal stent grafts: E-xtra Design Engineering, E-nside, Artivex, E-tegra, E-ventus BX, Tuva BX, E-liac
- On-X® mechanical heart valves and related surgical products
- Surgical sealants: BioGlue® Surgical Adhesive
- Implantable cardiac and vascular human tissues, including preservation services

## Other products and offerings

- PhotoFix® bovine surgical patches (sold or distributed)
- CardioGenesis® cardiac laser therapy (discontinued as of June 30, 2023)
- PerClot® hemostatic powder — manufacturing and supply began in Q2 2023 under the Transitional Manufacturing and Supply Agreement (TMSA) related to the Baxter transaction

## Corporate structure

Main operating subsidiaries include:
- JOTEC GmbH (Hechingen, Germany) — endovascular and surgical products; acquired December 1, 2017
- On-X Life Technologies, Inc. (On‑X LTI) — Austin, Texas; mechanical heart valve company; acquired January 20, 2016
- Ascyrus Medical GmbH — manufacturing entity; acquired September 2020

The company also maintains approximately twenty additional country entities to support global sales and marketing.

## Reportable segments

- Medical Devices — revenues from sales of aortic stent grafts, surgical sealants, On‑X products, and other product revenues  
- Preservation Services — revenues from preservation of cardiac and vascular implantable human tissues

## Geographic and operational footprint

Artivion operates through multiple country entities to support global sales and marketing, with a presence supported by the main subsidiaries listed above.

Artivion, Inc. is a global leader specializing in manufacturing, processing, and distributing medical devices and implantable human tissues used in cardiac and vascular surgeries for aortic diseases.

# Company Overview: Artivion, Inc.

## Business Focus
Artivion, Inc. is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgeries for patients with aortic disease.

---

## Major Product Families
1. **Aortic Stent Grafts:** 
   - Devices for endovascular repair of aortic aneurysms and dissections.
   - Includes aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts.
   - Notable products: E-vita Open NEO, E-vita Open Plus, NEXUS family (NEXUS ONE, DUO, TRE), E-vita Thoracic 3G, and custom-made products like Artivex and E-tegra.

2. **Surgical Sealants:** 
   - BioGlue Surgical Adhesive, used as an adjunct for wound sealing in surgeries involving large vessels, lungs, and the brain.

3. **On-X Mechanical Heart Valves:** 
   - Bileaflet mechanical valves made of pyrolytic carbon.
   - Includes aortic, mitral, and ascending aortic prostheses.
   - Features a lower INR management option for aortic valves, approved in the US in 2015.

4. **Implantable Human Tissues:** 
   - Human heart valves (CryoValve SG), patches (CryoPatch SG), and vascular tissues (CryoVein, CryoArtery) preserved through proprietary processes.
   - Used in valve replacements, cardiac reconstruction, peripheral vascular surgeries, and for patients with endocarditis.

## Additional Offerings
- PhotoFix bovine patches.
- PerClot hemostatic powder (manufactured starting Q2 2023, following Baxter acquisition).
- CardioGenesis cardiac laser therapy (discontinued as of June 2023).

---

## Operations & Geography
- **Employees:** Approximately 1,600 as of December 31, 2024.
  - Major facilities located in:
    - Kennesaw, Georgia (headquarters, tissue processing, BioGlue, PhotoFix, PerClot)
    - Austin, Texas (On-X manufacturing)
    - Hechingen, Germany (aortic stent graft manufacturing)
  - Other subsidiaries across Europe, APAC, and LATAM.

- **Revenue (2024):** $388.5 million (10% increase over 2023).
- **Net Income (2024):** Net loss of $13.4 million.

## Business Strategy
- Focused on four growth areas:
  - Developing new and next-generation products.
  - Expanding into new markets and indications.
  - Global expansion efforts, including regulatory approvals in China and Brazil.
  - Business development through acquisitions and licensing.

## Customer Base
- Supplies primarily to hospitals and healthcare providers worldwide.
- Has direct sales teams in North America, Europe, and other regions.
- Operates through distributors in APAC and LATAM.

## Revenue Breakdown
- **Products:** 75% of total revenue comprising aortic stent grafts, On-X valves, surgical sealants, and others.
- **Preservation Services:** 25% of total revenue, includes services for cardiac and vascular tissues.

---

## Regulatory & Market Position
- Listings on NYSE under symbol **AORT**.
- Raw materials often sourced from a global supply chain, including single-source suppliers.
- Manufacturing complies with US and international standards (FDA, ISO 13485).
- Holds CE Mark approvals for many products, with ongoing MDR transition.
- Products classified mainly as Class III medical devices, with some (e.g. BioGlue, On-X valves) approved by FDA.
- Continues to navigate complex international regulatory environments, including Brexit considerations.

---

## Summary Highlights
- **Employees:** ~1,600
- **Annual Revenue (2024):** $388.5 million
- **Net Income (2024):** Loss of $13.4 million
- **Market Capitalization (as of June 30, 2024):** ~$1.017 billion
- **Stock Symbol:** AORT
- **Customer Relationships:** Distributed through direct sales and regional/distributor channels globally.
- **Key Business Areas:** Cardiac and vascular surgical devices, tissue processing and preservation, and related surgical products.

ARTIVION, INC.

10-K / February 18, 2026

10-K / February 28, 2025

10-K / February 18, 2026

Artivion, Inc.

Product families

Other products and offerings

Corporate structure

Reportable segments

Geographic and operational footprint